{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:18:28Z","timestamp":1786997908959,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.vaccine.2022.08.069","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T04:56:55Z","timestamp":1662699415000},"page":"6179-6186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Development and application of a Japanese vaccine database for comparative assessments in the post-authorization phase: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study"],"prefix":"10.1016","volume":"40","author":[{"given":"Chieko","family":"Ishiguro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhisa","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.08.069_b0005","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/pds.5214","article-title":"Suitability of databases in the Asia-Pacific for collaborative monitoring of vaccine safety","volume":"30","author":"Duszynski","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2022.08.069_b0010","unstructured":"World Health Organization. Immunization Data Portal. \u201cHPV VACCINATION PROGRAM COVERAGE - LAST DOSE - FEMALES Target population who received the last dose of HPV vaccine in the reporting year\u201d 2020. https:\/\/immunizationdata.who.int\/pages\/coverage\/hpv.html?GROUP=WHO%20Regions&ANTIGEN=&YEAR=&CODE=."},{"key":"10.1016\/j.vaccine.2022.08.069_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2020.106399","article-title":"HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010\u20132019","volume":"144","author":"Bruni","year":"2021","journal-title":"Prev Med"},{"key":"10.1016\/j.vaccine.2022.08.069_b0020","unstructured":"Joint Council of Vaccine Adverse Reactions Review Committee and Pharmacovigilance Committee. Minutes of the Joint Council on May 16, 2013.Meeting material No.6-6 [in Japanese] 2013. https:\/\/www.mhlw.go.jp\/file\/05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakuka\/0000014810_1.pdf."},{"key":"10.1016\/j.vaccine.2022.08.069_b0025","unstructured":"Joint Council of Vaccine Adverse Reactions Review Committee and Pharmacovigilance Committee. Minutes of the 2nd meeting on June 14, 2013. [in Japanese] 2013. https:\/\/www.mhlw.go.jp\/stf\/shingi2\/0000091965.html."},{"key":"10.1016\/j.vaccine.2022.08.069_b0030","unstructured":"Ministry of Health, Labour and Welfare. Future Policy on Routine Vaccination for Human Papillomavirus Infection (Health Service Bureau Notification No. 1126-1) [in Japanese] 2021. https:\/\/www.mhlw.go.jp\/content\/000875155.pdf."},{"key":"10.1016\/j.vaccine.2022.08.069_b0035","unstructured":"Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Act No. 145 of 1960) (Revised on August 1st, 2021). E-Gov 2021. https:\/\/elaws.e-gov.go.jp\/document?lawid=335AC0000000145."},{"key":"10.1016\/j.vaccine.2022.08.069_b0040","unstructured":"Immunization Act (No.68 of 1948) (Revised on 9 December 2020) [in Japanese]. E-Gov 1948. https:\/\/elaws.e-gov.go.jp\/document?lawid=323AC0000000068."},{"key":"10.1016\/j.vaccine.2022.08.069_b0045","unstructured":"What is a signal? Uppsala Monitoring Centre 2022. https:\/\/who-umc.org\/signal-work\/what-is-a-signal\/."},{"key":"10.1016\/j.vaccine.2022.08.069_b0050","unstructured":"Safety signal. European Medicines Agency n.d. https:\/\/www.ema.europa.eu\/en\/glossary\/safety-signal#:\u223c:text=Safety%20signal.%20Information%20on%20a%20new%20or%20known,More%20information%20can%20be%20found%20under%20%27Signal%20management%27.?msclkid=e631a25dae6c11ec963750ff5e205f72."},{"key":"10.1016\/j.vaccine.2022.08.069_b0055","unstructured":"Centers for Disease Control and Prevention. Vaccine Safety Datalink (VSD) 2020. https:\/\/www.cdc.gov\/vaccinesafety\/ensuringsafety\/monitoring\/vsd\/index.html"},{"key":"10.1016\/j.vaccine.2022.08.069_b0060","unstructured":"Vac4EU. VAccine monitoring Collaboration for Europe 2019. https:\/\/vac4eu.org\/covid-19-vaccine-monitoring\/."},{"key":"10.1016\/j.vaccine.2022.08.069_b0065","unstructured":"Food and Drug Administration. Center for Biologics Evaluation and Research. The Biologics Effectiveness and Safety (BEST) Initiative 2017. https:\/\/bestinitiative.org\/."},{"key":"10.1016\/j.vaccine.2022.08.069_b0070","unstructured":"Enforcement Order for the immunization Law (Revised on April 1st 2021) 2021. https:\/\/elaws.e-gov.go.jp\/document?lawid=323CO0000000197."},{"key":"10.1016\/j.vaccine.2022.08.069_b0075","unstructured":"Ministry of Health, Labour and Welfare. Guideline for the National Routine Immunization Program (Revised on November 26, 2021) n.d. https:\/\/www.mhlw.go.jp\/bunya\/kenkou\/teiki-yobou\/10.html."},{"key":"10.1016\/j.vaccine.2022.08.069_b0080","unstructured":"Joint Council of Vaccine Adverse Reactions Review Committee and Pharmacovigilance Committee. Information Collection and Evaluation of Adverse Reactions on Vaccines [in Japanese]. 37th Meeting material No. 3-2 2020. https:\/\/www.mhlw.go.jp\/content\/10906000\/000588415.pdf."},{"key":"10.1016\/j.vaccine.2022.08.069_b0085","article-title":"The Longevity Improvement & Fair Evidence (LIFE) Study: Overview of the Study Design and Baseline Participant Profile (in print)","author":"Fukuda","year":"2022","journal-title":"J Epidemiol"},{"key":"10.1016\/j.vaccine.2022.08.069_b0090","unstructured":"Ministry of Health, Labour and Welfare. National Routine Immunization Procedure. Appendix 1 \u2018immunization reocrds\u2019 [in Japanese] 2022. https:\/\/www.mhlw.go.jp\/bunya\/kenkou\/teiki-yobou\/dl\/08a.pdf"},{"key":"10.1016\/j.vaccine.2022.08.069_b0095","unstructured":"Shimabukuro TT. End-of-season update: 2018-2019 influenza vaccine safety monitoring 2019."},{"key":"10.1016\/j.vaccine.2022.08.069_b0100","unstructured":"World Health Organization. Immunization, Vaccines and Biologicals. Table 1: Summary of WHO Position Papers - Recommendations for Routine Immunization 2021. https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/immunization_schedules\/immunization-routine-table1.pdf?sfvrsn=c7de0e97_9&download=true"},{"issue":"369","key":"10.1016\/j.vaccine.2022.08.069_b0105","first-page":"6","article-title":"Season Report of Suspected Adverse Reactions after Vaccination [in Japanese]","volume":"2018","author":"Ministry of Health","year":"2018","journal-title":"Pharm Med Dev Safety Inform"},{"key":"10.1016\/j.vaccine.2022.08.069_b0110","article-title":"Safety monitoring of COVID-19 vaccines in Japan","volume":"23","author":"Yamaguchi","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.vaccine.2022.08.069_b0115","unstructured":"European Medicines Agency. The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Guide on Methodological Standards in Pharmacoepidemiology (Revision 10) 2022."},{"key":"10.1016\/j.vaccine.2022.08.069_b0120","unstructured":"Health Sciences Council, Committee on Immunisation and Vaccines, Subcommittee on Basic Immunisation Policy, Vaccine evaluation group. Study on the relationship between rotavirus vaccines and enteric complications in Japan [in Japanese]. 9th Meeting Material No4-3 2018. https:\/\/www.mhlw.go.jp\/file\/05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakuka\/0000207078_1.pdf."},{"key":"10.1016\/j.vaccine.2022.08.069_b0125","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/cpt.2045","article-title":"The Certainty Framework for Assessing Real-World Data in Studies of Medical Product Safety and Effectiveness","volume":"109","author":"Cocoros","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.vaccine.2022.08.069_b0130","unstructured":"Pharmaceuticals and Medical Devices Agency. Basic Principles in Conducting a Validation Study on Outcome Definitions used in Post-marketing Database Study (Regulatory Science Center No. 0731002. Product Evaluation Center No. 0731002 on July 31, 2020) [in Japanese] 2020. https:\/\/www.pmda.go.jp\/files\/000235927.pdf."},{"key":"10.1016\/j.vaccine.2022.08.069_b0135","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22010775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22010775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:18:52Z","timestamp":1759403932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22010775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":27,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0264410X22010775"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.08.069","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and application of a Japanese vaccine database for comparative assessments in the post-authorization phase: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.08.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}